WO2023053828A1 - Dispositif de commande de chimiothérapie, système de commande de chimiothérapie, procédé de commande de dispositif de commande de chimiothérapie et programme de commande de chimiothérapie - Google Patents

Dispositif de commande de chimiothérapie, système de commande de chimiothérapie, procédé de commande de dispositif de commande de chimiothérapie et programme de commande de chimiothérapie Download PDF

Info

Publication number
WO2023053828A1
WO2023053828A1 PCT/JP2022/032664 JP2022032664W WO2023053828A1 WO 2023053828 A1 WO2023053828 A1 WO 2023053828A1 JP 2022032664 W JP2022032664 W JP 2022032664W WO 2023053828 A1 WO2023053828 A1 WO 2023053828A1
Authority
WO
WIPO (PCT)
Prior art keywords
unit
patient
chemotherapy
peripheral tissue
heating
Prior art date
Application number
PCT/JP2022/032664
Other languages
English (en)
Japanese (ja)
Inventor
伸一 金田
恵子 大津
Original Assignee
テルモ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テルモ株式会社 filed Critical テルモ株式会社
Publication of WO2023053828A1 publication Critical patent/WO2023053828A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F7/08—Warming pads, pans or mats; Hot-water bottles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F7/10—Cooling bags, e.g. ice-bags
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F7/12—Devices for heating or cooling internal body cavities
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body

Definitions

  • the present invention relates to a chemotherapy control device, a chemotherapy control system, a control method of the chemotherapy control device, and a chemotherapy control program for controlling the administration of anticancer drugs.
  • chemotherapy such as anticancer drug treatment may cause peripheral neuropathy in patients, which has become a problem.
  • Cooling of peripheral tissues is known to be a good preventive measure for peripheral neuropathy. Therefore, in the present invention, a chemotherapy control device, a chemotherapy control system, and a chemotherapy control device that can suppress the occurrence of peripheral neuropathy in a patient by cooling peripheral tissues while enhancing the therapeutic effect of chemotherapy.
  • the object is to provide a control method and a control program for a chemotherapy control device.
  • the object is, according to the present invention, to control at least a pump section that administers a drug and a heating section that heats a target site of a patient for hyperthermia treatment, and the operation of the pump section and the heating section.
  • a chemotherapy control device characterized in that it is configured to operate a peripheral tissue cooling unit for cooling peripheral tissue of said patient.
  • the peripheral tissue cooling unit for cooling the patient's peripheral tissue which is effective for suppressing the occurrence of peripheral neuropathy, is operated while the pump unit and the heating unit are in operation. Therefore, it is possible to prevent peripheral neuropathy or the like from occurring in a patient or the like when chemotherapy such as anticancer drug administration is performed.
  • the chemotherapy control device has an extravasation symptom detection unit that detects an extravasation symptom of the drug administered to the patient, and the extravasation symptom detection unit detects the extravasation symptom.
  • the operation of the pump unit is stopped when the operation is performed.
  • the extravasation symptom detection unit detects the extravasation symptom, the operation of the pump unit is stopped, so the safety of the patient to whom the drug is administered is ensured.
  • the operation of the heating unit and the peripheral tissue cooling unit is not stopped immediately after the sign of extravasation is detected and the operation of the pump unit is stopped. It is characterized by
  • the pump unit receives information from a body temperature information measuring unit arranged at a site different from a site of the patient that is heated by the heating unit and cooled by the peripheral tissue cooling unit.
  • the administration rate of the drug is controlled based on.
  • the administration rate of the drug is appropriately controlled based on the patient's body temperature and other conditions.
  • the state of the patient's body temperature, etc. is different from that of the target site of the heating unit or the peripheral tissue cooling unit, it is possible to acquire accurate body temperature information of the patient or the like.
  • the heating unit of the chemotherapy control device is configured to control heating based on body temperature information from a target tissue temperature measuring unit placed in the patient.
  • the heating unit controls the heating based on the body temperature information of the target tissue temperature measurement unit placed in the patient, so that the target site for treatment is set at a temperature effective for chemotherapy treatment. can do. Moreover, even when the heating unit is affected by the cooling of the peripheral tissue cooling unit, it is possible to prevent the temperature of the heating unit from dropping more than necessary.
  • the peripheral tissue cooling unit of the chemotherapy control device is configured to control the cooling temperature based on information from a peripheral tissue temperature measurement unit that acquires the temperature of the patient's peripheral tissue.
  • the peripheral tissue cooling unit controls the cooling temperature based on the information from the peripheral tissue temperature measuring unit that acquires the body temperature of the patient's peripheral tissue. Prevent temperature to be properly controlled. In addition, it is possible to prevent the temperature of the peripheral tissue cooling section from rising more than necessary due to the influence of the heating section.
  • a pump unit for administering a drug a heating unit for heating a target site of a patient for hyperthermia treatment
  • a chemotherapy control unit for controlling the pump unit and the heating unit.
  • the chemotherapy control device is configured to operate a peripheral tissue cooling section for cooling peripheral tissue of the patient during operation of the pump section and the warming section.
  • a chemotherapy control system characterized by:
  • the object is, according to the present invention, a control method for a chemotherapy control device for controlling at least a pump section for administering a drug and a heating section for heating a target site of a patient for hyperthermia treatment, comprising: This is achieved by a control method for a chemotherapy control apparatus, characterized in that a peripheral tissue cooling unit for cooling peripheral tissue of the patient is operated while the pump unit and the heating unit are in operation.
  • a chemotherapy control device for controlling at least a pump section for administering a drug and a heating section for heating a target site of a patient for hyperthermia treatment.
  • a chemotherapy control program for implementing the function of operating a peripheral tissue cooling unit that cools peripheral tissue of the patient during operation of the heating unit.
  • the present invention provides a chemotherapy control device, a chemotherapy control system, a control method for a chemotherapy control device, and a chemotherapy control that can suppress the occurrence of peripheral neuropathy in a patient while increasing the therapeutic effect of chemotherapy.
  • a control program for the device can be provided.
  • FIG. 1 is a schematic diagram showing the main configuration of, for example, an anticancer drug administration system 1, which is a chemotherapy control system.
  • FIG. 2 is a schematic block diagram showing the main configuration of a main controller 10 of FIG. 1;
  • FIG. 2 is a schematic flow chart showing an "anticancer drug administration step" of the present system 1; It is a schematic flowchart which shows a "heat treatment process.”
  • 2 is a schematic flow chart showing a "peripheral tissue cooling step”; 1 is a schematic flow chart showing a process for detecting extravasation of an anticancer drug during administration of the anticancer drug.
  • FIG. 1 is a schematic diagram showing a peripheral tissue cooling device, (a) is a glove-type peripheral tissue cooling device 30 worn on a patient's hand, and (b) is a boot-type peripheral tissue cooling device 40 worn on a patient's foot.
  • FIG. 1 is a schematic illustration of an "intravenous drip line" for administering an anticancer drug.
  • FIG. 1 is a schematic diagram showing the main configuration of, for example, an anticancer drug administration system 1, which is a chemotherapy control system. As shown in FIG. 1, the system 1 has, for example, a "main controller 10" which is a chemotherapy control device that controls the entire system.
  • the main controller 10 is communicably connected to a "control electronic terminal 11" for the user to control the system 1.
  • the control electronic terminal 11 is connected to an "electronic medical record information storage unit 12" that stores various medical information of the patient (medical history, medication history of drugs such as anticancer drugs, vital data, etc.).
  • the main controller 10 is configured to be able to access the "storage section (database) 13 for pharmacokinetic simulation information for each anticancer drug”.
  • the electronic medical record information storage unit 12 and the pharmacokinetic simulation information storage unit 13 for each anticancer drug shown in FIG. 1 are stored in, for example, a "host computer” (not shown) or the like.
  • the pharmacokinetics simulation information storage unit 13 for each anticancer drug stores "medicamental pharmacokinetics simulation information" for each anticancer drug, that is, information on drug behavior in the body (transition into tissue, etc.) and the like.
  • the main controller 10 controls, for example, a smart pump 14, which is a pump unit for administering the anticancer drug to the patient.
  • the smart pump 14 is an infusion pump or the like, and includes a so-called drug library (types of various drugs, various administration modes corresponding to various drugs, upper/lower limits of administration rates), and an upstream of the smart pump 14.
  • Equipped with occlusion pressure detection sensors that detect the occlusion pressure of the tube on the side and downstream side, and the upper limit of occlusion pressure etc. are stored in the storage unit, and the administration of anticancer drugs is controlled safely and accurately. ing.
  • the main controller 10 controls the following devices and the like.
  • the target tissue temperature measurement unit shown in FIG. “Vital sensors 23" for measuring respiratory rate, blood oxygen saturation, etc.), "Droplet sensor 24a” and “Micro pressure sensor 24b” arranged in the "intravenous drip line” for anticancer drugs to be described later. and "minute flow velocity sensor 24c".
  • the main controller 10 includes a body temperature information measuring unit such as an anticancer drug body temperature sensor 25, a peripheral tissue cooling unit such as a cooling pad 26, and a peripheral tissue body temperature measuring unit such as It is configured to also control the "skin temperature sensor 27" and the like.
  • the devices shown in FIG. 1, such as the skin temperature sensor 27, are communicably connected to the main controller 10 and the like by short-range wireless communication or the like. Note that this connection may be wired. Details of these devices will be described later.
  • main controller 10 control electronic terminal 11, smart pump 14, and other devices in FIG. Read Only Memory), etc., and these are connected via a bus or the like.
  • FIG. 2 is a schematic block diagram showing the main configuration of the main controller 10 of FIG. 1. As shown in FIG. The contents of each block shown in FIG. 2 will be described later.
  • 3 to 6 are schematic flow charts showing examples of main operations of the anticancer drug administration system 1 according to this embodiment.
  • An example in which the system 1 is used to administer an "anticancer agent" to a patient with stomach cancer, skin cancer, or the like will be described below in detail.
  • FIG. 3 is a schematic flow chart showing the "anticancer drug administration step” of the system 1.
  • the doctor in charge of the patient specifies the "patient ID” of the patient and the "anticancer drug” to be administered, and inputs them into the "electronic medical record information storage unit 12".
  • the process proceeds to step (hereinafter referred to as "ST") 1 in FIG.
  • ST1 the "individualized administration control pattern generation processing unit (program) 101" of the main controller 10 in FIG.
  • the "individualized administration control pattern” information of the patient is generated and stored in the "individualized administration control pattern storage unit 102" of FIG. .
  • pattern information such as tissue migration of the anticancer drug to the target tissue (affected area) such as the stomach and skin is generated and stored.
  • the "medicine administration processing unit (program) 103" of the main controller 10 operates, based on the “individualized administration control pattern", operates the “smart pump 14 (infusion pump, etc.)" of FIG.
  • the pump 14 is caused to administer the anticancer drug.
  • the "dosage” and “administration rate” of the anticancer drug are controlled so that they are within the optimal range.
  • the "medicine administration processing unit (program) 103" operates to acquire the "body temperature representative value as biological information" from the "anticancer drug body temperature sensor 25" in FIG.
  • the body temperature sensor 25 for the anticancer drug of the patient is placed at a "other site of the patient” different from the place where the "target tissue temperature measuring probe 21" and “cooling pad 26" described later are placed.
  • the "anti-cancer drug body temperature sensor 25" for grasping the state of the patient's body temperature, etc. measures the body temperature at a site different from the local heating pad 22 and the cooling pad 26, so that the patient's body temperature is more accurate. Information can be obtained.
  • the "drug administration processing unit (program) 103" considers the influence at regular intervals based on the "representative body temperature value as biological information" acquired from the "body temperature sensor for anticancer drug 25", Based on the in vivo pharmacokinetic simulation information 13 for each anticancer drug in FIG. 1, the administration rate control of anticancer drug administration is corrected.
  • the administration rate of the anticancer drug is appropriately controlled based on the patient's body temperature and other conditions.
  • the "medicine administration processing unit (program) 103" operates to determine whether administration of the specified amount of the anticancer drug has been completed. and terminate anticancer drug administration.
  • the "drug administration processing unit (program) 103" operates, and biological information (heart rate, blood pressure, body temperature, respiratory rate, blood oxygen saturation, etc.) and determines whether or not an abnormality has been detected. When an abnormality is detected, an alert is issued and the administration of the anticancer drug is suspended.
  • FIG. 4 is a schematic flow chart showing the "heat treatment process”.
  • the "thermal treatment process” of the anticancer drug will be described along FIG. “Cancer thermotherapy (hyperthermia) is a treatment method that uses high-frequency energy to heat and destroy cancer tissue. It is expected to play an important role in therapeutic therapy. For this reason, in the present embodiment, along with administration of an anticancer drug, a “thermal treatment” is performed by placing a "local heating pad 22" in FIG. 1 on a target site such as the stomach or skin.
  • the outer surface of the local heating pad 22 is covered with a heat insulating material such as a high-performance filling material or aluminum foil. It is a device that can raise the core body temperature without increasing the surface temperature as much as possible. are also located at positions corresponding to the target sites. For example, when using the topical heating pad 22 for stomach cancer or skin cancer, the topical heating pad 22 is placed only on the skin portion corresponding to the target site, the stomach, and only on the target site for skin cancer.
  • the local heating pad 22 is applied to the target tissue. It is preferable to use a device that can raise the temperature to a limited extent.
  • the "target tissue temperature measuring probe 21" shown in FIG. It is configured to measure the target tissue temperature of the target tissue.
  • the process proceeds to ST11 in FIG.
  • the "heat therapy processing unit (program) 104" in FIG. 2 operates to determine whether or not the "smart pump 14" is performing drug administration. Then, when it is determined that it has been executed, the process proceeds to ST12.
  • the "thermal treatment processing unit 104" in FIG. 2 operates to monitor the "target tissue temperature” acquired from the target tissue temperature measuring probe 21, and the resulting feedback information is "within the prescribed range". or not.
  • the present embodiment by controlling the heating based on the body temperature information of the local heating pad 22 placed on the patient, it is possible to obtain an effective temperature for chemotherapy treatment.
  • the topical heating pad 22 is affected by the cooling of the cooling pad 26, it is possible to prevent the temperature of the topical heating pad 22 from dropping more than necessary.
  • the temperature control of the local heating pad 22 is extremely important because the cancer is easily affected by the cooling of the cooling pad 26 .
  • the "thermal treatment processing unit (program) 104" operates, and any of the biological information (heart rate, blood pressure, respiratory rate, body temperature, blood oxygen saturation, etc.) that is vital information acquired from the vital sensors 23 If an abnormality is detected, an alert is issued and the operation of the local heating pad 22 is temporarily stopped. Specifically, it is determined whether or not the biometric information is within the preset criteria for the patient, and if it is not within the criteria, an emergency stop is made.
  • patient safety is ensured during hyperthermia treatment.
  • FIG. 5 is a schematic flow chart showing the "peripheral tissue cooling step".
  • the purpose is to suppress the occurrence of peripheral neuropathy or the like in patients due to the administration of anticancer agents. Since it is configured to cool the patient's peripheral tissues, such as extremities, at the same time as administering the anticancer drug, a specific description will be given below.
  • FIG. 7 is a schematic diagram showing a peripheral tissue cooling device, (a) is a glove-type peripheral tissue cooling device 30 worn on the patient's hand, and (b) is a boot-shaped peripheral tissue cooling device worn on the patient's foot.
  • a cooler 40 is provided.
  • the glove type and the boot type each have a plurality of "cooling pads 26" for cooling the peripheral tissues of the hands and feet, and measure the skin temperature of the hands and feet.
  • a skin temperature sensor 27 (such as a thermistor) is provided for this purpose.
  • the glove-type peripheral tissue cooling device 30 and the boot-type peripheral tissue cooling device 40 have built-in cooling pads 26 that can increase adhesion by pressurization in order to enhance the cooling effect on the skin.
  • a Peltier element is used as the cooling means for the cooling pad 26, the side opposite to the cooling portion becomes a heating portion. , radiating holes, etc.) (not shown) may be provided at appropriate locations to dissipate heat to the outside air, but the heat dissipating means is not limited to this.
  • the cooling effect can be enhanced by covering the outer surfaces of the glove-type peripheral tissue cooling device 30 and the boot-type peripheral tissue cooling device 40 with a heat-insulating member such as high-performance batting material or aluminum foil.
  • a heat insulating member such as aluminum foil may be placed on the outermost surface of the glove-type peripheral tissue cooling device 30 or the boot-type peripheral tissue cooling device 40, and these may be used as radiators at the same time.
  • the pressure is so light that it does not cause extravasation due to pressure and can ensure adhesion. is pressurized.
  • the peripheral tissue cooling process will be described along FIG. In ST21 of FIG. 5, the "peripheral tissue cooling processing unit (program) 105" of FIG. 2 operates, and the “smart pump 14" determines whether drug administration is being performed. Then, if it is executed, the process proceeds to ST22. In ST22, the "peripheral tissue cooling processor (program) 105" operates, and cools the patient through the cooling pad 26 of the glove-type peripheral tissue cooler 30 or the boot-type peripheral tissue cooler 40 shown in FIG. Cools the peripheral tissues of the extremities.
  • ST23 the "temperature” obtained from the skin temperature sensors 27 of the glove-type peripheral tissue cooling device 30 and the boot-type peripheral tissue cooling device 40 is monitored, and whether or not the resulting feedback information is "within a prescribed range". is determined, and if it is out of the specified range, the output (temperature) of the cooling pad 26 is adjusted and controlled within the specified range.
  • the skin temperature is controlled to a cooling temperature within a specified range, for example, 10 to 16 degrees. This control is executed for each glove-type peripheral tissue cooler 30 and boot-type peripheral tissue cooler 40 .
  • the cooling pad 26 for cooling the patient's peripheral tissue is operated while the smart pump 14 and the local heating pad 22 are operating. At the time of administration, it is possible to prevent the development of peripheral neuropathy or the like in patients.
  • the "peripheral tissue cooling processing unit (program) 105" operates, and an abnormality is detected in the biological information (heartbeat, blood pressure, respiratory rate, blood oxygen saturation, etc.) which is vital information acquired from the vital sensors 23. If so, it issues an alert and suspends operation of the cooling pad 26 at the same time.
  • patient safety is ensured during peripheral tissue cooling.
  • FIG. 6 is a schematic flow chart showing steps for detecting extravasation of an anticancer drug during administration of the anticancer drug.
  • FIG. 8 is a schematic illustration of an "intravenous infusion line" for administering an anticancer drug.
  • the intravenous drip line serves as a drug administration circuit from a "drip tube 24d" containing an anticancer drug to an "administration needle 24e" for actually administering the anticancer drug to the patient.
  • a “droplet sensor 24a” is attached to the drip tube 24d
  • an in-line “micro pressure sensor 24b” installed in the drug administration circuit and a “microflow velocity sensor 24c” using an ultrasonic wave or a temperature sensor are installed. It has become.
  • These "droplet sensor 24a", “micro pressure sensor 24b”, and “micro flow rate sensor 24c” function as an extravasation sign detector.
  • the extravasation detection step will be described with reference to FIG. First, go to ST31.
  • the extravasation symptom detection unit in FIG. 2 for example, the "extravasation detection processing unit (program) 106" operates to determine whether or not the "smart pump 14" is performing drug administration. .
  • the extravasation sign detection units which are the "droplet sensor 24a", the “micro pressure sensor 24b”, and the “micro flow rate sensor 24c” in FIG. It determines whether there is a sign of extravasation by capturing changes in fluid flow rate and back pressure. In this manner, since the presence or absence of signs of "extravasation" is determined by a plurality of sensors installed in the intravenous drip line, highly accurate determination is possible.
  • signs of "extravasation” are determined from the sensor installed in the intravenous drip line, but the present invention is not limited to this.
  • the target site of drug administration (stomach, skin, etc.) is intended to be protected so as not to hinder the movement of the administration needle 24e and catheter of the indwelling needle due to body movement and the influence of the cooling pad 26 (peripheral tissue cooling method).
  • a protective pad is attached, and a temperature sensor may be incorporated in this protective pad to detect temperature changes at the administration site and use it for early detection of signs of extravasation.
  • ST33 administration of the anticancer drug is immediately stopped immediately, but cooling of the extremities (cooling pad 26) and thermal treatment of the target site (local heating pad 22) are stopped after a certain period of time (about 30 minutes). program to let
  • the cooling or heating operation is performed for a certain period of time after the operation of the smart pump 14 is stopped, not immediately. Therefore, the effects of chemotherapy with anticancer agents are not lost immediately, and the occurrence of peripheral neuropathy and the like in patients is continuously suppressed.
  • the operation of the smart pump 14 is stopped, so that the safety of the patient during the administration of the anticancer drug can be ensured. Become.
  • the program that can be executed by a computer is a magnetic disk (floppy (registered (trademark) disk, hard disk, etc.), optical disk (CD-ROM, DVD, etc.), magneto-optical disk (MO), semiconductor memory, or other storage medium.
  • the storage medium may be any computer-readable storage medium that can store the program.
  • the storage format of the storage medium is not particularly limited.
  • the OS operating system
  • MW middleware
  • database management software such as database management software, network software, etc.
  • a part of each process may be executed, and the cloud may be used.
  • the storage medium in the present invention is not limited to a medium independent of a computer, and includes a storage medium in which a program transmitted via LAN, Internet, etc. is downloaded and stored or temporarily stored.
  • the computer in the present invention may execute each process in the present embodiment based on a program stored in a storage medium, and may be a device consisting of a single personal computer (PC) or the like, or a plurality of devices. may be a system or the like connected to a network.
  • PC personal computer
  • the computer in the present invention is not limited to a personal computer, but includes an arithmetic processing unit included in information processing equipment, a microcomputer, an arithmetic processing system on the cloud, etc., and can realize the function of the present invention by a program. equipment, devices, and systems.
  • Reference Signs List 1 anticancer drug administration system 10 main controller 11 control electronic terminal 12 electronic medical record information storage unit 13 pharmacokinetics simulation information for each anticancer drug Storage unit 14 Smart pump 21 Probe for measuring target tissue temperature 22 Local thermal pad 23 Vital sensors 24a Droplet sensor 24b Micro pressure sensor 24c Micro flow rate sensor 24d Infusion tube 24e Administration needle 25 Body temperature sensor for anticancer drug 26 Cooling pad 27 Skin temperature sensor 30 glove-type peripheral tissue cooling device 40 boot-type peripheral tissue cooling device 101 individualized administration control pattern generation processing unit 102 individualized administration control pattern storage unit 103... drug administration processing unit, 104... hyperthermia treatment processing unit, 105... peripheral tissue cooling processing unit, 106... extravasation detection processing unit

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Thermal Sciences (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)

Abstract

Un dispositif de commande de chimiothérapie (10) commande au moins une unité de pompe (14) pour administrer un médicament et une unité de chauffage (22) pour chauffer un site cible d'un patient pour une thérapie par hyperthermie, et actionne une unité de refroidissement de tissu périphérique (26) pour refroidir un tissu périphérique du patient pendant une opération de l'unité de pompe et de l'unité de chauffage.
PCT/JP2022/032664 2021-09-30 2022-08-30 Dispositif de commande de chimiothérapie, système de commande de chimiothérapie, procédé de commande de dispositif de commande de chimiothérapie et programme de commande de chimiothérapie WO2023053828A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021160896 2021-09-30
JP2021-160896 2021-09-30

Publications (1)

Publication Number Publication Date
WO2023053828A1 true WO2023053828A1 (fr) 2023-04-06

Family

ID=85780603

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/032664 WO2023053828A1 (fr) 2021-09-30 2022-08-30 Dispositif de commande de chimiothérapie, système de commande de chimiothérapie, procédé de commande de dispositif de commande de chimiothérapie et programme de commande de chimiothérapie

Country Status (1)

Country Link
WO (1) WO2023053828A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009219664A (ja) * 2008-03-17 2009-10-01 Terumo Corp 薬剤注入装置
JP2011224333A (ja) * 2010-03-29 2011-11-10 Terumo Corp 血管外漏出検出装置及び輸液システム
JP2018027925A (ja) * 2016-08-19 2018-02-22 株式会社明治 抗がん剤に起因する末梢神経障害を改善するための組成物
JP2018528774A (ja) * 2015-09-09 2018-10-04 シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート 免疫療法のためのマクロファージの遺伝子組換え
JP2021127540A (ja) * 2020-02-16 2021-09-02 株式会社エバンス 冷却用足装着具

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009219664A (ja) * 2008-03-17 2009-10-01 Terumo Corp 薬剤注入装置
JP2011224333A (ja) * 2010-03-29 2011-11-10 Terumo Corp 血管外漏出検出装置及び輸液システム
JP2018528774A (ja) * 2015-09-09 2018-10-04 シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート 免疫療法のためのマクロファージの遺伝子組換え
JP2018027925A (ja) * 2016-08-19 2018-02-22 株式会社明治 抗がん剤に起因する末梢神経障害を改善するための組成物
JP2021127540A (ja) * 2020-02-16 2021-09-02 株式会社エバンス 冷却用足装着具

Similar Documents

Publication Publication Date Title
US11844722B2 (en) Method and system to detect changes in a patient's endogenous temperature set-point during externally induced targeted temperature management
US8317776B2 (en) Circulatory monitoring systems and methods
US8636670B2 (en) Circulatory monitoring systems and methods
US20090287191A1 (en) Circulatory monitoring systems and methods
US20090287109A1 (en) Circulatory monitoring systems and methods
US20100036209A1 (en) Circulatory monitoring systems and methods
US20100036269A1 (en) Circulatory monitoring systems and methods
US20090287101A1 (en) Circulatory monitoring systems and methods
US20090292222A1 (en) Circulatory monitoring systems and methods
JP2007516023A (ja) 哺乳動物の身体との制御された熱伝達
US20090287093A1 (en) Circulatory monitoring systems and methods
US20100036268A1 (en) Circulatory monitoring systems and methods
US20200245950A1 (en) Real-time body temperature management
US20090292214A1 (en) Circulatory monitoring systems and methods
US20240238117A1 (en) Determining a value indicative of a thermoregulatory activity of a patient using a temperature management system
US20090287110A1 (en) Circulatory monitoring systems and methods
US20090287094A1 (en) Circulatory monitoring systems and methods
US20100036263A1 (en) Circulatory monitoring systems and methods
Taguchi et al. Negative pressure rewarming vs. forced air warming in hypothermic postanesthetic volunteers
US20090292213A1 (en) Circulatory monitoring systems and methods
WO2023053828A1 (fr) Dispositif de commande de chimiothérapie, système de commande de chimiothérapie, procédé de commande de dispositif de commande de chimiothérapie et programme de commande de chimiothérapie
Wadhwa et al. New circulating-water devices warm more quickly than forced-air in volunteers
WO2017055488A1 (fr) Système et de procédé de perfusion à réglage de volume
Milligan et al. Performance comparison of improvised prehospital blood warming techniques and a commercial blood warmer
Hansen et al. Thermal burn associated with intraoperative convective forced-air warming blanket (Bair Paws™ Flex Gown System)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22875700

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22875700

Country of ref document: EP

Kind code of ref document: A1